Clinical Trials Browser

Phase 3 × Neoplasms × lenvatinib × Clear all

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms